Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence.

The European Federation of Organisations for Medical Physics (EFOMP) has published a statement on the role of dosimetry in radionuclide therapy (RNT), emphasizing the need for personalized dosimetry to plan and monitor RNT. The statement is based on European Council directive 2013/59/Euratom, which states that exposures to non-target volumes and tissues should be as low as reasonably achievable (ALARA) while still achieving the intended therapeutic purpose. The article discusses the difference in evidence for selective internal radiation therapy (SIRT) and radiopharmaceutical therapy (RPT), with SIRT having proven benefits in terms of tumor control probability, non-tumor complication probability, and progression-free survival or overall survival. However, the clinical benefit of dosimetry in RPT is not yet demonstrated. The article also highlights the importance of clinical data in guiding treatment planning for RPT and emphasizes the need for more clinical trials and research in the field. [Extracted from the article]